中国全科医学2011，Vol.14Issue(1)：62-63,2.
拉米夫定耐药慢性乙型肝炎应用阿德福韦酯的疗效研究
Efficacy of Adefovirdipivoxilin Therapy for Patients with Chronic Hepatitis B Resistant to Lamivudine
覃华 1李端 2杜德伟3
作者信息
- 1. 710038陕西省西安市,第四军医大学唐都医院药剂科
- 2. 710038陕西省西安市,第四军医大学唐都医院传染科
- 3. 710038陕西省西安市,第四军医大学唐都医院肾内科
- 折叠
摘要
Abstract
Objective To observe the efficacy and safety of adefovirdipivoxilin therapy for patients with chronic hepatitis B resistant to lamivudine. Methods Randomized, doubleblind, lamivudine controlled study was conducted in 86 chronic hepatitis B patients. Eligihle patients stopped lamivudine therapy and were randomly assigned to respectively receive oral 10mg of adefovirdipivoxil once daily and oral 100mg of lamivudine once daily for 6 months. Serum HBV DNA , hepatitis B serology markers and ALT level were measured at regular intervals, the adverse events were recorded at the same time. Results After 3 month treatment, the responding rates of serum HBV DNA were 65. 1％ ( 28 cases ) in adefovirdipivoxil group and 30. 2％ ( 13 cases) in lamivudine group ( X2 = 10. 488, P = 0. 002 ). And after 6 - month treatment, the responding rates of serum HBV DNA were 88. 4％ ( 38 cases ) in adefovirdipivoxil group and 51. 2％ ( 22 cases ) in lamivudine group ( X2 = 14. 113, P = 0. 000 ), but no statistical significance was found in HBeAg sero conversion rate between the two groups ( P = 0. 192 ). Conclusion Adefovirdipivoxil was safe and efficative for lamivudine - resistant patients with chronic hepatitis B.关键词
肝炎,乙型,慢性/拉米夫定耐药/阿德福韦酯分类
医药卫生引用本文复制引用
覃华,李端,杜德伟..拉米夫定耐药慢性乙型肝炎应用阿德福韦酯的疗效研究[J].中国全科医学,2011,14(1):62-63,2.
